Are you already a client or interested in our services? We are happy to help you.
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
0800 17 37Belgium
+32 (0)32 86 69 80Switzerland
+41 (0)43 377 11 11We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 80 00United States of America
+1 (0)21 237 601 34Joint Global Coordinator and Joint Bookrunner
Kempen & Co is pleased to announce that it acted as Joint Global Coordinator and Joint Bookrunner in Xbrane’s SEK 380m Capital Increase
Xbrane is a biopharmaceutical company that develops biosimilars based on a proprietary platform. Xbrane’s lead product - Xlucane - a biosimilar candidate to Lucentis®, addresses ophthalmic VEGFa inhibitor market. Marketing authorization and launch of Xlucane is expected for H2 2022. Xlucane is partnered with biosimilar specialist STADA and ophthalmology specialist Bausch+Lomb for commercialization. Xbrane's pre-clinical candidates include Xcimzane - biosimilar to Cimzia currently under development, and Xdivane - a biosimilar to Opdivo. Xbrane's ambition is to initiate one new biosimilar development program annually and become cash-flow positive by late 2023/early 2024
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: